Abstract #3492
The Effect of the Chemotherapy Agent Methotrexate on the Developing Brain
Leigh Spencer Noakes 1 , Brian J. Nieman 1,2 , Ellen van der Plas 3 , Shoshana Spring 1 , and Russell Schachar 4
1
Mouse Imaging Centre, The Hospital for Sick
Children, Toronto, Ontario, Canada,
2
Medical
Biophysics, University of Toronto, Toronto, Ontario,
Canada,
3
Psychiatry, The Hospital for Sick
Children, Toronto, Ontario, Canada,
4
Psychiatry,
University of Toronto, Toronto, Ontario, Canada
Chemotherapy is used to treat the most common childhood
cancer, acute lymphoblastic leukemia (ALL), with a
success rate of 90%. Unfortunately, survivors are at
high risk of developing late effects, which are
prominent in children and cause slowed learning as well
as other cognitive effects. The goal of this project is
to determine if a portion of the population can be
identified prior to treatment as sensitive to
methotrexate treatment by genetic testing combined with
MRI analysis of brain during development.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Click here for more information on becoming a member.
